Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE:7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.

“Adding a fourth patent to our portfolio demonstrates the calibre of Filament’s intellectual property strategy and drug development platform,” “Our ability to transform valuable natural substances into IP-protected pharmaceutical-grade drug candidates sets us apart as industry leaders.”

Ryan Moss, Chief Science Officer at Filament Health

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. On August 3, 2021, Filament was issued the first-ever patent for the extraction and standardization of natural psilocybin, and since then the Company has been issued a further two patents by CIPO and one by the United States Patent and Trademark Office.

“Since Filament’s founding, we have endeavoured to identify the most efficient means to extract naturally sourced fungal APIs,” said Taran Grey, Director of Intellectual Property. “We are proud to add a patent that covers yet another novel process that we use to produce drug candidates.”

Completion of Annual Third Party Audit

Filament Health subsidiary Psilo Scientific recently completed an annual third-party audit of its manufacturing facility by Eurofins against Canadian and European Union Good Manufacturing Practices (GMP). Following the audit, Filament received a letter of compliance from the auditor demonstrating that its facility meets the requirements for the GMP manufacturing of natural psychedelic drug candidates.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.